GTC
SMMT icon

Ghost Tree Capital’s Summit Therapeutics SMMT Stock Holding History

Ghost Tree Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.86M Buy
+85,000
New +$1.19M 0.56% 47

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Ghost Tree Capital's SMMT Position: Q3 2024 in Review

Ghost Tree Capital opened a new position in Summit Therapeutics (SMMT) in Q3 2024: 85,000 shares worth $1.86M. The stake represents 0.56% of the portfolio and ranks #47 among its holdings.

166 funds tracked by Wall St. Rank hold SMMT as of Q3 2024.

  • Ghost Tree Capital held 85,000 shares of Summit Therapeutics worth $1.86M as of Q3 2024.
  • Summit Therapeutics was a new Ghost Tree Capital position in Q3 2024.
  • Summit Therapeutics made up 0.56% of Ghost Tree Capital's portfolio in Q3 2024, its #47 holding.
  • 166 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.